VirEOS

A research consortium under the “Excellence of Science” (EOS) initiative, uniting Belgian experts in virology and molecular interactions.

We investigate various aspects of SARS-CoV-2 infection, from host pathogenesis to detailed molecular mechanisms of cell infection by the virus.

We also develop vaccines and antiviral molecules to combat SARS-CoV-2 and related viruses that could emerge.

VirEOS Research Project

VirEOS : Preparedness to viral pandemics

Advancing our understanding of SARS coronavirus antigenic and pathogenic evolution: A major concern is the emergence of SARS-CoV-2 variants, which are less susceptible to infection- and vaccine-induced immunity. Next to this uncertainty on how the virus will continue to evolve, the very high patient-to-patient variability in disease severity upon SARS-CoV-2 infection is poorly understood. In this project, we will tackle these two key aspects to anticipate on SARS-CoV-2 evolution and guide future therapies for those patients that are most at risk. In addition, fundamental aspects of coronavirus infection will be studied to prepare a specific response against infections by these viruses.

Research Highlight

Single-Molecule Investigation of the Binding Interface Stability of SARS-CoV-2 Variants with ACE2

A major issue concerning COVID-19 is the sustainability of the immune response generated after infection or after vaccination. In a research conducted by two teams of the VirEOS project, single-molecule force spectroscopy was used to analyse the interaction strength of spike variants with the Ace2 receptor. This study suggests that vaccination before infection may provide stronger protection across variants.